Date: 2017-05-16
Type of information: Opening of new premises
Compound: commercial production site for biopharmaceuticals in China
Company: Boehringer Ingelheim (Germany)
Therapeutic area: Technology - Services
Type agreement: opening of new premises
Action mechanism:
Disease:
Details:
- • On May 16, 2017, Boehringer Ingelheim inaugurated its commercial production site for biopharmaceuticals in Zhang Jiang Hi-tech Park of Shanghai (China). The site, with the first-phase investment of more than €70 million, is the first and only biopharmaceutical facility established by a leading multinational active biopharmaceutical manufacturer in China utilizing mammalian cell culture technology.
- Boehringer Ingelheim has now a global network of biopharmaceutical production with sites in Biberach ( Germany), Vienna (Austria), Fremont (USA) and now Shanghai. The german group has made this strategic move with the long-term goal to become a leader for contract development and manufacturing of monoclonal antibodies and recombinant proteins in China. Since 2014, Boehringer Ingelheim China Biopharmaceuticals has been operating its Good Manufacturing Practice (GMP) clinical material supply at 100L and 500L scales. After its inauguration, the facility will operate for clinical and commercial supply on a 2000L single-use bioreactor scale. It is designed to flexibly add additional 2000L single-use bioreactors and fill/finish capabilities to meet increasing market demand.
Financial terms:
Latest news:
Is general: Yes
